Ketamine: Repurposing and redefining a multifaceted drug

Drug Discovery Today

Volumn 19, Issue 12, 2014, Pages 1848-1854

  Potter, David E ^a   Choudhury, Mahua ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMITRIPTYLINE; AMPA RECEPTOR; BACLOFEN; CLONIDINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GABAPENTIN; HALOPERIDOL; IONOTROPIC RECEPTOR; KAPPA OPIATE RECEPTOR; KETAMINE; KETOPROFEN; LIDOCAINE; MICRORNA; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PLASMA PROTEIN; PREGABALIN; SIGMA 1 OPIATE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNTRANSLATED RNA; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASIC RESEARCH; BINDING AFFINITY; BINDING SITE; BIPOLAR DEPRESSION; CLINICAL RESEARCH; COMPLEX REGIONAL PAIN SYNDROME; DEPRESSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG REPOSITIONING; DRUG SOLUBILITY; DRUG UPTAKE; EPIGENETICS; HUMAN; IMMUNOMODULATION; LIPID SOLUBILITY; MAJOR DEPRESSION; MEDICINAL CHEMISTRY; NEUROPATHIC PAIN; NONHUMAN; PAIN; PERINEAL PAIN; TREATMENT RESISTANT DEPRESSION; WITHDRAWAL SYNDROME; ANIMAL; ANTAGONISTS AND INHIBITORS;

ANALGESICS; ANESTHETICS, DISSOCIATIVE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; DRUG REPOSITIONING; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84911377164     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.017     Document Type: Short Survey

References (60)

1. B.H. Munos Pharmaceutical innovation gets a little help from new friends Sci. Transl. Med. 5 2013 1 2
2. F. Aroni Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug J. Clin. Pharmacol. 49 2009 957 964
3. K. Hirota, and D.G. Lambert Ketamine: new uses for an old drug? Br. J. Anaesth. 107 2011 123 126
4. D.A. McCarthy General anesthetic and other pharmacological properties of 2-(o-chlorophenyl)-2-methylamino cyclohexanone HCL (CI-581) J. New Drugs 5 1965 21 33
5. G. Corssen, and E.F. Domino Dissociative anesthesia: further pharmacologic studies and first clinical experience with phencyclidine derivative CI-581 Anesth. Analg. 45 1966 29 40
6. E.F. Domino Pharmacological effects of CI-581, a new dissociative anesthetic in man Clin. Pharmacol. Ther. 6 1965 279 291
7. G. Salvatore, and J.B. Singh Ketamine as a fast acting antidepressant: current knowledge and open questions CNS Neurosci. Ther. 19 2013 428 436
8. C. Jamora, and M. Iravani Unique clinical situations in pediatric patients where ketamine may be the anesthetic agent of choice Am. J. Ther. 17 2010 511 515
9. B. Sinner, and B.M. Graf Ketamine Handb. Exp. Pharmacol. 182 2008 313 333
10. X. Duan Dexmedetomidine provides neuroprotection: impact on ketamine-induced neuroapoptosis in the developing rat brain Acta Anaesthesiol. Scand. 2014 10.1111/aas.12356
11. R.H. Kronenberg Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration J. Pain Pall. Care Pharmacother. 16 2002 27 35
12. J. Sawynok Topical and peripheral ketamine as an analgesic Pain Med. 119 2014 170 178
13. S.H. Preskorn Ketamine: the hopes and the hurdles Biol. Psychiatry 72 2012 522 523
14. T.J. Poterucha Topical amitryptiline-ketamine for treatment of rectal, genital, and perineal pain and discomfort Pain Physician J. 15 2012 485 488
15. S. Himmelseher, and E. Pfenninder The clinical use of S-(+)-ketamine: the determination of its place Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 33 1998 764 770
16. M.J. Robson Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo Eur. Neuropsychopharmacol. 22 2012 308 317
17. C.A. Zarate Jr. Relationship of ketamine's plasma metabolites with response, diagnosis and side effects in major depression Biol. Psychiatry 72 2012 331 338
18. X. Chen HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine J. Neurosci. 29 2009 600 609
19. J. Persson Ketamine in pain management CNS Neurosci. Therap. 19 2013 396 402
20. R.M. O'Conner microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive therapy in the rat hippocampus Int. J. Neuropsychopharmacol. 16 2013 1885 1892
21. R.S. Duman, and B. Voleti Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents Trends Neurosci. 35 2011 47 56
22. G.Z. Reus Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors Behav. Brain Res. 256 2013 451 456
23. J. Kocerha MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction Proc. Natl. Acad. Sci. U. S. A. 106 2009 3507 3512
24. X. Yang MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BNDF by ketamine Neuromol. Med. 16 2014 594 605
25. C. Yang Ketamine attenuates the lipopolysaccharide-induced inflammatory response in cultured N2a cells Mol. Med. Rep. 8 2013 217 220
26. L. Roytblat Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass Anesth. Analg. 87 1998 266 271
27. E. Carlo Epigenetics in sepsis: targeting histone deacetylases Int. J. Antimicrob. Agents 42 Suppl. 2013 S8 S12
28. M. De Kock Ketamine and peripheral inflammation CNS Neurosci. Therap. 19 2013 403 410
29. J.H. Krystal NMDA antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy Ann. N. Y. Sci. 1003 2003 176 184
30. E.M. Krupitsky Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence J. Psychoactive Drugs 39 2007 13 19
31. J. Quinlan The use of a sub-anesthetic infusion of intravenous ketamine to allow withdrawal of medicinally prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: outcome at 6 months Pain Med. 13 2012 1524 1525
32. H. Weisman Anesthesia for pediatric ophthalmology Ann. Ophthalmol. 3 1972 229 232
33. D.B. Carr Safety and efficacy of intranasal ketamine for treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study Pain 108 2004 17 27
34. K. Christensen Safety and efficacy of intranasal ketamine for acute postoperative pain Acute Pain 9 2007 183 192
35. J. Johansson Prehospital analgesia using nasal administration of S-ketamine - a case series Scand. J. Trauma Resuscit. Emerg. Med. 21 2013 1 4
36. K. Behaeen Analgesic effect of low dose subcutaneous ketamine administration before and after Cesarean section Iran Red Crescent Med. J. 16 2014 1 5
37. Q.A. Tawfic A review of the use of ketamine in pain management J. Opioid Manage. 9 2013 379 388
38. R. Poyhia, and A. Vainio Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia Clin. J. Pain 22 2006 32 36
39. X. Wang, and L. Black Ex vivo percutaneous absorption of ketamine, bupivacaine, diclofenac, gabapentin, orphenadrine and pentoxifylline: comparison of versatile cream vs. reference cream Int. J. Pharm. Compound. 17 2013 520 525
40. D.L. Barton A double-blind, placebo-controlled trail of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N066CA Support. Care Cancer 19 2011 833 841
41. W. Zur Complex regional pain syndrome Type I following trauma: a case report Lat. J. Pharm. Compound. 18 2014 14 19
42. L. Hershman Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guidelines J. Clin. Oncol. 18 2014 1941 1967
43. M.E. Goldberg Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome Pain Physician 8 2005 175 179
44. J.W. Murrough Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression Biol. Psychiatry 74 2013 250 256
45. C.A. Browne, and I. Lucki Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Front. Pharmacol. 4 2013 1 18
46. M.M. Bellet Ketamine influences CLOCK: BMAL1 function leading to altered circadian gene expression PLoS ONE 2011 10.1371/journal.pone.0023982
47. S.M. Zakhary A behavioral and molecular analysis of ketamine in zebrafish Synapse 65 2011 160 167
48. B. Jung-Hynes, and N. Ahmad SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms FASEB J. 23 2009 2803 2809
49. N. Carrier, and M. Kabbaj Sex differences in the antidepressant-like effects of ketamine Neuropharmacology 70 2013 27 34
50. R.M. Berman Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354
51. N. Diazgranados Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder J. Clin. Psychiatry 71 2010 1605 1611
52. S. Maeng Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol. Psychiatry 63 2008 349 352
53. L.M. Monteggia The role of eukaryotic elongation factor 2 kinase in the rapid antidepressant action of ketamine Biol. Psychiatry 73 2013 1199 1203
54. L.S.B. Garcia Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32 2008 140 144
55. X. Deng MiR-21 involve in ERK-mediated upregulation of MMP9 in the rat hippocampus following cerebral ischemia Brain Res. Bull. 94 2013 56 62
56. N. Li mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
57. M.J. Niciu Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds Annu. Rev. Pharmacol. Toxicol. 54 2014 119 139
58. C. Caddy Ketamine as the prototype glutaminergic antidepressant: pharmacodynamics actions, and a systematic review and meta-analysis of efficacy Ther. Adv. Psychopharmacol. 4 2014 75 99
59. H.W.W. Hasselmann Ketamine as an antidepressant? Current state and future perspectives Curr. Neuropharmacol. 12 2014 57 70
60. R. Machadao-Viera Ketamine and the next generation of antidepressants with a rapid onset of action Pharmacol. Ther. 123 2009 143 150